(0 items)
Small Medium Large | Print-Friendly Version of this Page  | Email this Page to a Friend
Skip Navigation Links
Press Releases
Hot Topics
Statements
Comments
Correspondence
White Papers
Contact Public Relations
AABB > Press Room > Correspondence

Correspondence 

This section contains letters that have been sent or received by AABB on issues of concern to the transfusion medicine and cellular therapies communities.

Letter from CareFusion Announcing FDA Approval to Update ChloraPrep Label to Thirty Second Dry Time – 11/1/13 (PDF)
Letter From Boston Medical Center Commending AABB Members and the NBE for Providing Assistance After the Boston Marathon Bombings - 5/1/13 (PDF)
Letter to CDER in Response to Class-Wide Label Change for Skin Antiseptic Products Containing Alcohol - 1/10/13
Letter to Congress Supporting Legislation to Allow for More Reasonable Proficiency Testing Referral Penalties - 10/3/12
Letter to Congress Supporting Bill to Expand Requirements to Report Studies to Clinicaltials.gov - 10/3/12
Letter to IRS Regarding Medical Device Excise Tax - 8/20/12
FDA Response to AABB TTD Request for Review of Blood Relative vs. First Degree Relative in CJD Screening - 4/20/12 (PDF)
Letter to The Joint Commission Regarding Proposed Blood Transfusion Service and Donor Center Standards  – 10/22/10
Letter From U.S. Rep. Van Hollen Urging CDC to Enhance Collaboration with Private Sector on Hemovigilance – 7/21/10 (PDF)
Letter to Congress Calling for Maintenance of Funding for Vector-Borne Diseases Program at CDC – 4/9/10
AABB Asks Test Manufacturers to Bring Additional HTLV–I/II Tests to the U.S. Market – 8/31/09 (PDF)
Letter to Facilities with ISBT 128 Variance – 7/16/09
Letter to Facilities with ISBT 128 Status Unknown – 7/16/09
Letter from CMS Clarifying MUE Policy – 4/14/09 (PDF)
Letter to HRSA on Specifications for Accreditation of Cord Blood Banks – 4/10/09
Response from the National Quality Forum Regarding the Definition of a Transfusion–Related Event – 3/5/09 (PDF)
Letter to the National Quality Forum Regarding the Definition of a Transfusion–Related Event – 2/12/09
Letter to FDA from the AABB Ad Hoc Task Force to Propose an Alternate Post–Market Study Design for Seven–Day Platelets – 4/28/08
FDA Response to Letter from AABB Bacterial Contamination Standard Task Force to FDA on Approval Strategies for Point–of–Release Testing for Bacterial Contamination – 4/24/08 (PDF)
Letter to the FDA Nominating Industry Representatives to BPAC – 2/28/08
Letter to the FDA on a Draft Template for a Shorter Inter–donation Interval During an Influenza Pandemic – 2/14/08
Follow up to the Letter from AABB Bacterial Contamination Standard Task Force to Gambro BCT and Fenwal in Response to the Discontinuation of the Passport Study – 2/13/08
Letter to FACT Proposing Accreditation Partnership – 2/4/08
Letter from AABB Bacterial Contamination Standard Task Force to Gambro BCT and Fenwal in Response to the Discontinuation of the Passport Study – 1/31/08
Letter from AABB Bacterial Contamination Standard Task Force to FDA on Approval Strategies for Point–of–Release Testing for Bacterial Contamination – 12/26/07
Letter to the AMA on Cord Blood Banking – 11/16/07
Letter to Verax Biomedical, Inc. Regarding the Platelet PGD® Test – 10/3/07 (PDF)
Letter to HHS on the Appointment of the Advisory Council on Blood Stem Cell Transplantation – 10/2/07
Letter to CMS Requesting Proper Categorization of the eBDS Test System – 9/14/07
Letter to FDA in Response to the Report of the Human Tissue Task Force – 7/6/07
Letter to Facilities Selected for Inclusion in 2007 NBCUS – 3/7/07 (PDF)

 
Home  |  Site Map  | AABB © 2014. All rights reserved. |  Privacy Statement  |  Terms of Use